OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Lynparza"

The PARP inhibitor, Olaparib ( Lynparza ) has shown clinical activity in subsets of recurrent ovarian cancer patients. Researchers have hypothesized increased DNA damage by Olaparib may complement a ...


Positive results from the phase 3 PAOLA-1 trial in women with advanced ovarian cancer. were announced. The trial, in the first-line maintenance setting, compared Olaparib ( Lynparza ) added to stand ...


TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted agents in patients with advanced cancers with genomic alterations. R ...


Pembrolizumab ( Keytruda ) plus Olaparib ( Lynparza ) has shown antitumor activity and acceptable safety in Docetaxel-pretreated pts with metastatic castration-resistant prostate cancer ( mCRPC ) enro ...